Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUX-Lung 7: Afatinib vs Gefitinib in EGFR+ Lung Cancer
NCT01466660Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2011
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 14
01
Overview
A Phase 2 trial of afatinib in lung adenocarcinoma, sponsored by Boehringer Ingelheim. Started Dec 2011; status: completed.
02
Drugs
afatinib
03
Conditions
lung adenocarcinoma
Beyond the preview
Go deeper on NCT01466660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01466660.